A
Agnes Buzyn
Researcher at Necker-Enfants Malades Hospital
Publications - 71
Citations - 2636
Agnes Buzyn is an academic researcher from Necker-Enfants Malades Hospital. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 27, co-authored 71 publications receiving 2473 citations. Previous affiliations of Agnes Buzyn include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia - Results of the GRAAPH-2003 study
Adrienne de Labarthe,Philippe Rousselot,Francoise Huguet-Rigal,Eric Delabesse,Francis Witz,Sébastien Maury,Delphine Rea,Jean-Michel Cayuela,M C Vekemans,Oumedaly Reman,Agnes Buzyn,Arnaud Pigneux,Martine Escoffre,Yves Chalandon,Elizabeth Macintyre,Véronique Lhéritier,Jean-Paul Vernant,Xavier Thomas,Norbert Ifrah,Hervé Dombret +19 more
TL;DR: This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context.
Journal ArticleDOI
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Kheira Beldjord,Sylvie Chevret,Vahid Asnafi,Françoise Huguet,Marie-Laure Boulland,Thibaut Leguay,Xavier Thomas,Jean-Michel Cayuela,Nathalie Grardel,Yves Chalandon,Nicolas Boissel,Beat W. Schaefer,Eric Delabesse,Hélène Cavé,Patrice Chevallier,Agnes Buzyn,Thierry Fest,Oumedaly Reman,Jean-Paul Vernant,Véronique Lhéritier,Marie C. Béné,Marina Lafage,Elizabeth Macintyre,Norbert Ifrah,Hervé Dombret +24 more
TL;DR: It is indicated that genetic abnormalities are important predictors of outcome in adult ALL not fully recapitulated by early response to therapy, as assessed by immunoglobulin/T-cell receptor minimal residual disease (MRD) levels.
Journal ArticleDOI
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
Emmanuelle Tavernier,Jean-Michel Boiron,F. Huguet,Kenneth F. Bradstock,Norbert Vey,Tibor Kovacsovics,André Delannoy,Nathalie Fegueux,Pierre Fenaux,Aspasia Stamatoullas,Olivier Tournilhac,Agnes Buzyn,Oumedaly Reman,C. Charrin,Claude Boucheix,Jean Gabert,Véronique Lhéritier,J P Vernant,Hervé Dombret,Xavier Thomas +19 more
TL;DR: It is concluded that most adult patients with recurring ALL could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option.
Journal ArticleDOI
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Vahid Asnafi,Vahid Asnafi,Agnes Buzyn,Sandrine Le Noir,Sandrine Le Noir,Frederic Baleydier,Frederic Baleydier,Arnauld Simon,Kheira Beldjord,Kheira Beldjord,Oumedaly Reman,Francis Witz,T. Fagot,Emmanuelle Tavernier,Pascal Turlure,Thibaut Leguay,Françoise Huguet,Jean-Paul Vernant,Francis Daniel,Marie-Christine Béné,Norbert Ifrah,Xavier Thomas,Hervé Dombret,Elizabeth Macintyre,Elizabeth Macintyre +24 more
TL;DR: It is demonstrated that notCH1 pathway activation by either NOTCH1 or FBXW7 mutation identifies a large group of patients with a favorable outcome that could justify individual therapeutic stratification for T-ALL.
Journal ArticleDOI
CD4+CD25+ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation
Sébastien Maury,François M. Lemoine,Yosr Hicheri,Michelle Rosenzwajg,Cécile Badoual,Mustapha Cherai,Jean-Louis Beaumont,Nabih Azar,Nathalie Dhedin,Anne Sirvent,Agnes Buzyn,Marie-Thérèse Rubio,Stephane Vigouroux,Olivier Montagne,Dominique Bories,Françoise Roudot-Thoraval,Jean-Paul Vernant,Catherine Cordonnier,David Klatzmann,José L. Cohen +19 more
TL;DR: A preliminary study shows that depleting donor lymphocytes of inhibitory regulatory T cells can be a safe and effective way to free active T cells from inhibition so that they can fight cancer cells in the recipient.